The translocator protein (TSPO) (18 kDa) is an emerging drug target for the treatment of numerous pathologies including cancer and neurodegenerative disease. However, our limited knowledge of TSPO binding site(s) has hindered the development of TSPO ligands with potential therapeutic effects. We have synthesized a series of pyrrolobenzoxazepines (1-10) to better characterize the interaction of ligands with the TSPO across species, and to determine their functional profiles.
Evidence for complex binding profiles and species differences at the translocator protein (TSPO) (18 kDa) / AM Scarf; C Luus; E Da Pozzo; S Selleri; C Guarino; C Martini; LM Ittner; M Kassiou.. - In: CURRENT MOLECULAR MEDICINE. - ISSN 1566-5240. - ELETTRONICO. - 12:(2012), pp. 488-493.
Evidence for complex binding profiles and species differences at the translocator protein (TSPO) (18 kDa).
SELLERI, SILVIA;
2012
Abstract
The translocator protein (TSPO) (18 kDa) is an emerging drug target for the treatment of numerous pathologies including cancer and neurodegenerative disease. However, our limited knowledge of TSPO binding site(s) has hindered the development of TSPO ligands with potential therapeutic effects. We have synthesized a series of pyrrolobenzoxazepines (1-10) to better characterize the interaction of ligands with the TSPO across species, and to determine their functional profiles.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Evidenceforcomplex_CMM2012.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
423.3 kB
Formato
Adobe PDF
|
423.3 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
